Insider · CIK 0001123343
Gary A Lyons
director
Files at NBIX (NEUROCRINE BIOSCIENCES INC), TVTX (Travere Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 22, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +1,435 | $0.00 | $0 | 120,482 | May 22, 2025 |
| May 21, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restricted Stock Unitderivative | +1,659 | $0.00 | $0 | 1,659 | May 22, 2025 |
| May 21, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Non-Qualified Stock Optionderivative | +3,305 | $0.00 | $0 | 3,305 | May 22, 2025 |
| May 22, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -1,435 | $0.00 | $0 | 0 | May 22, 2025 |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 57,500 | May 16, 2025 |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | May 16, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.